Prognostic Factors After Neoadjuvant Imatinib for Newly Diagnosed Primary Gastrointestinal Stromal Tumor.
Michael J CavnarKenneth SeierMithat GönenChristina CurtinVinod P BalachandranWilliam D TapCristina R AntonescuSam SingerRonald P DeMatteoPublished in: Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (2020)
In primary GIST undergoing Neo-IM therapy, progression was uncommon, but substantial down-sizing occurred in the minority. High tumor mitotic rate and incomplete resection following Neo-IM were associated with poor outcome, while adjuvant imatinib was associated with prolonged survival.